Santhera Pharmaceuticals Holding AG (SPHDF) Comparison with companies in other sectors?

Santhera Pharmaceuticals Holding AG has a share price of 12.93M. You can analyze Santhera Pharmaceuticals Holding AG (SPHDF) competitors across different market sectors through stock heatmaps.

What are SPHDF's NET and operating margins?

Santhera Pharmaceuticals Holding AG (SPHDF) operating margin is around 0.28, and net profit margin is approximately 0.27 as of the latest reports.

In what way does SPHDF's earnings per share (EPS) trend reflect its financial momentum?

Santhera Pharmaceuticals Holding AG (SPHDF) EPS is -4.62 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Santhera Pharmaceuticals Holding AG is -3.19, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Santhera Pharmaceuticals Holding AG?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Santhera Pharmaceuticals Holding AG like P/E which is 3.62, P/B which is 5.51, and PEG which is 0.04. Compare them with sector averages to evaluate if the stock is priced fairly.

Santhera Pharmaceuticals Holding AG

SPHDF•PNK

Healthcare

Biotechnology

$14.75

$0.00(0.00%)

Fundamental Analysis of Santhera Pharmaceuticals Holding AG (SPHDF)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-4.62

P/E Ratio

-3.19

ROE

0.89%

Net Margin

0.27%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$190.71M

Shares OutstandingTotal number of shares issued

$12.93M

Book Value/ShareNet worth per share

$2.68

Revenue/ShareAnnual revenue per share

$14.84

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-4.62

Net MarginNet income as percentage of revenue

27.44%

Operating MarginOperating income as percentage of revenue

27.95%

ROEReturn on shareholders' equity

89.06%

ROAReturn on total assets

27.64%

ROCEReturn on capital employed

40.37%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.20

Cash/ShareCash and equivalents per share

$3.95

FCF YieldFree cash flow as percentage of market cap

-1.18%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SPHDFFinancial Ratios Analysis details for SPHDF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SPHDFSector Benchmarking details for SPHDF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Santhera Pharmaceuticals Holding AG Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Santhera Pharmaceuticals Holding AG. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Santhera Pharmaceuticals Holding AG's unique business strengths and challenges.

Key Financial Metrics for Santhera Pharmaceuticals Holding AG

For Santhera Pharmaceuticals Holding AG, essential financial indicators include EPS -4.62, PE -3.19, and ROE 0.89. These key ratios reveal insights into Santhera Pharmaceuticals Holding AG's profitability, valuation, and operational health. Understanding these metrics enables you to compare Santhera Pharmaceuticals Holding AG with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Santhera Pharmaceuticals Holding AG

Metrics like Net Margin 27.44% and ROA 27.64% shed light on how well Santhera Pharmaceuticals Holding AG is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Santhera Pharmaceuticals Holding AG can sustain its operations and continue growing in the future.

Valuation and Market Position of Santhera Pharmaceuticals Holding AG

Using ratios such as P/B Ratio 5.51 and PEG Ratio 0.04, investors can assess whether Santhera Pharmaceuticals Holding AG is appropriately valued based on its financials and growth potential. These figures, combined with Santhera Pharmaceuticals Holding AG's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Santhera Pharmaceuticals Holding AG

Financial health indicators, such as Debt/Equity Ratio 1.47 and Cash Flow $-0.20, provide a snapshot of Santhera Pharmaceuticals Holding AG's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Santhera Pharmaceuticals Holding AG, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Santhera Pharmaceuticals Holding AG

Investing in Santhera Pharmaceuticals Holding AG based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Santhera Pharmaceuticals Holding AG focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;